{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.36","value":"81.0"},{"groupId":"OG001","spread":"18.31","value":"80.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"title":"Baseline Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.69","value":"0.4"},{"groupId":"OG001","spread":"14.28","value":"-0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Change at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.61","value":"0.6"},{"groupId":"OG001","spread":"14.38","value":"-0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"Change at Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.81","value":"-0.9"},{"groupId":"OG001","spread":"13.30","value":"-3.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Change at Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.48","value":"-2.0"},{"groupId":"OG001","spread":"8.37","value":"-2.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Change at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.93","value":"-10.2"},{"groupId":"OG001","spread":"33.82","value":"-8.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Change at Cycle 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.52","value":"-1.8"},{"groupId":"OG001","spread":"5.66","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Change at Cycle 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.43","value":"-13.6"},{"comment":"Not calculable due to single participant","groupId":"OG001","spread":"NA","value":"-4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Change at Cycle 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.25","value":"0.0"},{"groupId":"OG001","spread":"1.41","value":"-2.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Change at Cycle 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.53","value":"-10.1"},{"groupId":"OG001","spread":"21.40","value":"-11.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Change at EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"description":"The EQ-5D VAS score records the participant's self-rated health on a vertical visual analogue scale, with 0 being the worst imaginable health state and 100 being the best imaginable health state. A positive change indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Tebentafusp administered at 20 mcg at Cycle 1 Day 1, 30 mcg at Cycle 1 Day 8, and 68 mcg at Cycle 1 Day 15 by IV infusion and weekly thereafter.","id":"OG000","title":"Tebentafusp"},{"description":"1 of 3 Investigator's Choice options: Systemic Dacarbazine, Ipilimumab or Pembrolizumab. Dacarbazine: administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity; Ipilimumab: administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments; Pembrolizumab: administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity.","id":"OG001","title":"Investigator's Choice"}],"paramType":"MEAN","populationDescription":"The Intent-to-treat (ITT) Analysis Set comprises all participants assigned to treatment analyzed by the treatment assignment whether or not the participant received the assigned treatment. Combining participants into a single group as part of the Investigator's Choice arm was pre-specified as part of the study design; therefore, data per different treatments were not analyzed.","reportingStatus":"POSTED","timeFrame":"EQ-5D,5L VAS was assessed at baseline (Cycle 1 Day 1) and on Day 1 of every other cycle to Cycle 5 Day 1, every fourth cycle thereafter, beginning with Cycle 9 Day 1 and End of Treatment (EOT), up to 36 months. Each cycle is 21 days.","title":"Quality-of-life: Change From Baseline in EQ-5D Visual Analogue Score (VAS)","type":"SECONDARY","unitOfMeasure":"Units on a scale"}